Medscape

First-Line Osimertinib Plus Chemo Extends Survival in NSCLC

The final overall survival (OS) results of the FLAURA2 trial support osimertinib plus chemotherapy as the new first-line standard of care for EGFR-mutated non-small cell lung cancer (NSCLC), according ...
Medscape

Osimertinib's Benefits in NSCLC Can Extend Beyond First Line

Data from the COMPEL trial support extending osimertinib (Tagrisso, AstraZeneca) therapy to patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progress on first-line treatment ...

Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript

Immuneering Corporation ( IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer June 1, 2026 8:00 AM EDT ...